septerna - Search News

News

Novo Nordisk Inks A Major Obesity Deal

Reuters on MSN · 2h

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

The Wall Street Journal on MSN · 5h

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Seeking Alpha on MSN · 5h

Novo Nordisk in pact with Septerna for oral obesity drugs

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more here.

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

5h

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

Indianapolis Business Journal1h

Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results